Abstract 478P
Background
Lung cancer is commonly diagnosed after 40 years old and surgical lung resection is the recommended treatment for early stage lung cancer. The mean age of presentation is around 70 years old but there remained concerns on performing surgery in these patients. These concerns were addressed with advances in surgical technique and we aimed to review our experience of performing curative lung resection in patients above 70 years old.
Methods
We performed a retrospective review of all patients who underwent curative surgery for primary lung cancers between 2018 and 2021 and compared the outcome between patients 70 years old and above against those who were younger.
Results
289 were reviewed, of which 180 patients (62.3%) were under 70 years old and 109 patients (37.7%) were 70 years old and above. Patients above 70 years had a significantly higher incidence of hypertension, hyperlipidemia, diabetes mellitus, ischaemic heart disease and renal impairment but there was no significant difference in the incidence of previous stroke, atrial fibrillation, congestive heart failure and chronic obstructive pulmonary disease. There was also no significant difference between the pre-operative FEV1 and DLCO between the 2 groups of patients. Patients above 70 years old were at higher risk of developing pneumonia (OR 2.28, 95% CI 1.65-3.13, p = 0.003), respiratory failure (OR 2.71, 95% CI 2.33-3.16, p = 0.020) and unplanned return to the ICU (OR 2.41, 95% CI 1.78-3.27, p = 0.005). Peri-operative mortality was also higher in patients above 70 years old but this was statistically not significant. (OR 1.94, CI 1.18-3.17, p = 0.073). There was no significant difference in the post-operative incidence of cardiac, renal or wound complications. No patients developed a peri-operative stroke.
Conclusions
Our study demonstrated that patients above 70 years old may be more susceptible to pulmonary complications such as pneumonia and respiratory failure that may in turn lead to higher peri-operative mortality. Care can be taken to mitigate these complications such as pre-operative pulmonary rehabilitation and early mobilisation but this should not preclude patients above 70 years old from undergoing curative lung resection surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract